Diagnostic Imaging Agent Pulled from Market
The FDA has issued a Public Health Advisory to inform health care providers the agency has requested the market withdrawal of the diagnostic imaging agent NeutroSpec (Technetium (99m TC) Fanolesomab) pending review of reported deaths and serious and life-threatening adverse events associated with use of the product.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.